JPMorgan Chase & Co. Lowers Stake in Sionna Therapeutics, Inc. $SION

JPMorgan Chase & Co. decreased its position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 10.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,978,626 shares of the company’s stock after selling 242,562 shares during the period. JPMorgan Chase & Co. owned 4.43% of Sionna Therapeutics worth $58,191,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of SION. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics in the 3rd quarter valued at $30,000. BNP Paribas Financial Markets acquired a new stake in shares of Sionna Therapeutics during the second quarter worth $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sionna Therapeutics during the second quarter worth $45,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Sionna Therapeutics in the third quarter valued at $147,000. Finally, Virtus Investment Advisers LLC purchased a new stake in shares of Sionna Therapeutics in the second quarter valued at $96,000.

Sionna Therapeutics Trading Up 3.2%

Shares of Sionna Therapeutics stock opened at $35.49 on Friday. The business’s fifty day moving average price is $38.23 and its 200 day moving average price is $36.19. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $45.00. The stock has a market capitalization of $1.60 billion and a P/E ratio of -18.20.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Insider Buying and Selling

In related news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the sale, the insider owned 6,494,962 shares of the company’s stock, valued at approximately $259,798,480. This represents a 3.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc sold 29,063 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the completion of the transaction, the director owned 3,530,702 shares in the company, valued at $157,398,695.16. The trade was a 0.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 378,618 shares of company stock valued at $15,731,751. 3.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SION. Citigroup assumed coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They set an “outperform” rating on the stock. Guggenheim upped their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Raymond James Financial reissued a “strong-buy” rating and issued a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. Finally, Lifesci Capital raised shares of Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $50.57.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.